Articles from NMDP

A new campaign will portray the patient journey through the eyes of the virtual influencer, helping to educate and inspire her young fans to save a life through blood stem cell donation

MINNEAPOLIS, May 06, 2025 (GLOBE NEWSWIRE) -- NMDPSM hosted its annual gala in New York on Thursday, May 1, raising $525,000-- funds which will support patient financial assistance and innovative cell therapy research to improve post-transplant outcomes and expand treatment access so every patient can receive their life-saving cell therapy. In 2024, NMDP provided $6.6 million in patient assistance to 3,300 patients and their families, more than any year prior.

MINNEAPOLIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- NMDPSM, a global nonprofit leader in cell therapy, announced today executive leadership news – including introducing Alexander Rosenstein as general counsel and chief compliance officer and adding strategic responsibilities under Erica Jensen, senior vice president of strategy and advancement – resulting in a streamlined team at the helm of the 40 year-old organization. Rosenstein and Jensen are filling existing executive roles and responsibilities.

AFCA’s Support of NMDP Get in the Game Invites College Coaches and Student Athletes to Help Give More Patients a Second Chance at Life Through Blood Stem Cell Donations

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will present new data showing a donor search prognosis score helps physicians move patients with blood cancers and diseases to hematopoietic cell transplant (HCT) more quickly with alternative donors, resulting in no difference in any outcomes like overall survival (OS) at two years post-evaluability. Investigators from the consortium of U.S. transplant centers, CIBMTR® (Center for International Blood and Marrow Transplant Research®), the Emmes Company and NMDPSM that make up the BMT CTN, used an NMDP-developed donor search prognosis score based on patients’ human leukocyte antigen (HLA) type and self-identified race/ethnicity to determine patients’ likelihood of identifying an HLA-matched (8/8) unrelated donor (MUD). By turning to alternative donors when the chance of finding a MUD is low, patients were able to achieve similar survival rates, results which will be presented orally today at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego.

MINNEAPOLIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NMDP℠ (formerly Be The Match), a global nonprofit leader in cell therapy, raised $1.1 million during its 17th annual fundraising gala last month at The Depot Minneapolis. Coupled with NMDP Unite events across the country and worldwide World Marrow Donor Day celebrations, it was a historic day for the organization. The funds raised will go directly to patient assistance grants, innovative research in cell therapy, and expanding the diversity of the NMDP Registry. In 2023, NMDP provided $5.5 million in assistance to more than 2,600 families.

All-star athletes Naz Reid, Breanna Stewart and Gabby Douglas joining simultaneous celebrations in Minneapolis, New York City and Los Angeles on September 21.

Global cell therapy nonprofit honored in top 3 of the 'extra large' companies, recognizing its exceptional employees, workplace culture and life-saving mission

Funds raised enable more patients to receive life-saving cell therapy

Research results from NMDP℠ and CIBMTR® (Center for International Blood and Marrow Transplant Research®)—published today in the peer-reviewed Journal of Clinical Oncology—found no discernable difference in overall survival (OS) among patients with blood cancer receiving blood stem cell transplant when investigators used an unrelated donor matched at 7/8 human leukocyte antigen (HLA) markers, compared to a fully matched 8/8 unrelated donor when using a post-transplant cyclophosphamide-based (PTCy) graft-versus-host disease (GVHD) prevention strategy. Conducted by CIBMTR—a research collaboration between the Medical College of Wisconsin® and NMDP—the observational study also showed no discernable differences in GVHD-free, relapse-free survival (GRFS) for adults with blood cancers who had a 7/8 or an 8/8 unrelated donor transplant when using PTCy.

NMDPSM, a global nonprofit leader in cell therapy, announced today it hired two new executives – Katherine Heyerdahl as chief financial officer (CFO) and Jim Graham as chief information officer (CIO) – to its executive team, where they will play pivotal roles in driving the organization’s mission-critical operational strategy. Heyerdahl and Graham are filling existing executive leadership roles.

NMDPSM, a global nonprofit leader in cell therapy, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®), announced that interim results from the ACCESS trial will be presented as an oral abstract on Friday, May 31 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Ill., demonstrating that adults with hematologic malignancies who received peripheral blood stem cell (PBSC) transplant from HLA-mismatched unrelated donors (MMUD) followed by post-transplant cyclophosphamide (PTCy) graft-versus-host-disease (GvHD) prophylaxis exhibited a 79% overall survival, with a significant 51% GvHD-free, relapse-free survival (GRFS) probability at one-year post transplant. Notably, ASCO also selected this abstract to be presented at its 2024 Best of ASCO program in July.

Oscar-nominated and Emmy-winning filmmaker Matthew Heineman honored for American Symphony: Become a Lifesaver campaign in collaboration with Memorial Sloan Kettering Cancer Center and Higher Ground

MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online. A chief focus will be sharing interim findings from ACCESS, the prospective, multi-center, Phase II clinical trial of HCT using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children.

Riders can select from six routes to help raise funds and bring awareness to NMDP’s lifesaving mission

The Moore family’s donation accelerates NMDP’s lifesaving mission

NMDP also recognizes its first Barbara Buchbinder Nurse Research Grant recipient, helping improve patient experience and outcomes

Groundbreaking Trial Seeks to Enhance Blood Cancer Treatment Efficacy and Safety

Tom Hochuli will lead the organization as it renews its commitment to advancing cell and gene therapy

The organization’s new unified identity reflects its groundbreaking research, treatment and patient support to cure blood cancers and blood disorders